Why in News?

On 26 February 2026, Ministry of External Affairs put India-Israel Joint Statement in the spotlight through an official communication. The development is relevant because it speaks directly to themes that UPSC regularly tests in both factual and analytical form.

The official source, titled India – Israel Joint Statement (February 26, 2026), helps place the issue in a wider policy context. For aspirants, the topic is useful not only for remembering the headline event but also for connecting it to governance, economy, diplomacy, infrastructure, environment, or social policy as required.

UPSC Relevance

• Prelims: countries, summits, joint statements, institutions, agreements, and locations in news
• Mains: GS II on bilateral relations, strategic partnerships, and foreign policy

What Happened?

A Special Strategic Partnership for Peace, Innovation, and Prosperity 1. Recognising the warmth, goodwill, and deep strategic partnership between India and Israel, the Prime Minister Shri Narendra Modi made a state visit to Israel from 25 to 26 February 2026 on the invitation of Mr.

Benjamin Netanyahu, Prime Minster of the State of Israel. The Prime Minister was accompanied by a high-level delegation comprised of senior ministers and officials.

Why it Matters

For UPSC, the bigger takeaway is that one diplomatic development often reveals the wider direction of India's external engagement, strategic priorities, and response to geopolitical change. In exam terms, this topic can strengthen both short factual notes and longer answer-writing examples.

Bottom Line

India-Israel Joint Statement is relevant because it combines immediate current-affairs value with wider exam utility. For UPSC, the bigger takeaway is that one diplomatic development often reveals the wider direction of India's external engagement, strategic priorities, and response to geopolitical change.

Exam Oriented Questions

Why in News?

On 26 February 2026, Ministry of External Affairs put Key Outcomes of the Prime Minister's Visit to Israel in the spotlight through an official communication. The development is relevant because it speaks directly to themes that UPSC regularly tests in both factual and analytical form.

The official source, titled List of Outcomes: Visit of Prime Minister to Israel (February 25 – 26, 2026), helps place the issue in a wider policy context. For aspirants, the topic is useful not only for remembering the headline event but also for connecting it to governance, economy, diplomacy, infrastructure, environment, or social policy as required.

UPSC Relevance

• Prelims: countries, summits, joint statements, institutions, agreements, and locations in news
• Mains: GS II on bilateral relations, strategic partnerships, and foreign policy

What Happened?

Elevation of relationship to Special Strategic Partnership 2. JCM on Science and Technology elevated to Ministerial level 3.

Initiative to collaborate in Critical and Emerging Technologies led by National Security Advisors 4. 20 Joint Fellowships in Agricultural Research 7.

Why it Matters

For UPSC, the bigger takeaway is that one diplomatic development often reveals the wider direction of India's external engagement, strategic priorities, and response to geopolitical change. In exam terms, this topic can strengthen both short factual notes and longer answer-writing examples.

Bottom Line

Key Outcomes of the Prime Minister's Visit to Israel is relevant because it combines immediate current-affairs value with wider exam utility. For UPSC, the bigger takeaway is that one diplomatic development often reveals the wider direction of India's external engagement, strategic priorities, and response to geopolitical change.

Exam Oriented Questions

Why in News:

The Indian government is set to launch a nationwide HPV (Human Papillomavirus) vaccination campaign, initially targeting girls of 14 years old, to combat cervical cancer. This initiative marks a significant step towards public health and cancer prevention in India.

UPSC Relevance:

 GS-I Social Issues, GS-II Health

What Is HPV?

Human Papillomavirus (HPV) is a group of viruses — several strains of which are classified as high-risk because they can cause cervical cancer, as well as other cancers (e.g., vulvar, vaginal, anal). Persistent infection with HPV types 16 and 18 accounts for the majority of cervical cancer cases in India and globally.

What is cervical cancer and why does it matter?

Cervical cancer is a major public health issue in India:

• It’s the second most common cancer among Indian women.
• About 80,000 new cases and over 42,000 deaths are reported annually in the country.
• India accounts for roughly one-third of global cervical cancer cases.

HPV is a sexually transmitted virus, but infection doesn’t always lead to cancer. With vaccination and screening, most cases are preventable.

What Is the Indian Government Doing?

In February-March 2026, the Union Government of India is rolling out a nationwide HPV vaccination campaign with the goal of cutting cervical cancer cases in future generations.

Key Features of the Programme

1. Target Group:
   • Adolescent girls aged 14 years will be eligible for vaccination during the initial phase.
   • In subsequent discussions at state levels, some areas may extend campaigns to slightly broader age groups (e.g., 9-14), but the national push focuses on 14-year-olds.
2. Vaccine Used:
   • Gardasil-4 (quadrivalent HPV vaccine) protecting against HPV types 6, 11, 16 and 18 is being used.
   • Types 16 and 18 are most commonly linked to cervical cancer, while 6 and 11 cause warts.
3. Schedule:
   • A single-dose schedule is being followed for this campaign — based on WHO recommendations showing that one dose offers durable protection in the recommended age group.
4. Cost and Access:
   • The vaccine is free and voluntary for eligible girls at government health facilities like primary centres, district hospitals, and Ayushman Arogya Mandirs.
   • Registration and scheduling can be done via the U-WIN portal (similar to the COVID-19 CoWIN system).
5. Partnership:
   • The vaccine doses are being supplied under collaboration with Gavi, the Vaccine Alliance.
     • Gavi, the Vaccine Alliance is a massive public-private global health partnership created in 2000 to improve access to new and underused vaccines for children living in the world’s poorest countries

 Why a Single Dose?

The World Health Organization (WHO) updated its guidance to allow single-dose HPV vaccination for ages 9-20, based on evidence that it provides protection comparable to multiple doses in these age groups.

This approach:

• Improves coverage and logistics (especially in a large country like India).
• Reduces costs and drop-outs from multi-dose schedules.
• Increases the feasibility of vaccinating millions of eligible girls in schools and health centres.

How does HPV vaccination help in cervical cancer prevention?

HPV vaccination is considered one of the most effective preventive interventions ever developed for cancer. Global studies show 93–100% effectiveness in preventing cervical lesions caused by vaccine-covered HPV types.

If high coverage is achieved:

• Future cervical cancer incidence could decline dramatically.
• Related hospitalisations and deaths would fall significantly.

Why must HPV vaccination be complemented with cervical cancer screening?

• Vaccination does not eliminate the need for cervical cancer screening (e.g., Pap smear tests), especially for older women who missed vaccination.
• Screening detects early changes before they become cancerous.

This two-pronged strategy (vaccination + screening) is central to cancer control. (General public health principle)

 Preventive Health Focus in line with global goals:

The initiative underscores India’s shift toward preventive healthcare, aligning with global goals (like UN SDG 3 on good health and well-being) and the WHO global strategy to eliminate cervical cancer.

WHO’s Global Strategy (90-70-90 Targets by 2030):

• 90% of girls fully vaccinated with the HPV vaccine by 15 years of age.
• 70% of women screened with a high-performance test by 35, and again by 45 years of age.
• 90% of women with pre-cancer treated and 90% of women with invasive cancer managed.

What are the key challenges in implementing a nationwide HPV vaccination drive in India?

While the drive marks a major milestone, some challenges remain:

• Awareness and acceptance: Misconceptions about HPV and vaccination can affect uptake in socially conservative contexts.
• Cold chain and logistics: Ensuring vaccine integrity across remote areas requires strong infrastructure.
• Integration with existing health programmes: The campaign is not yet fully integrated into the Universal Immunisation Programme; linking with adolescent health programmes is essential for sustainability.  

There have also been discussions about integrating the indigenous CERVAVAC vaccine developed by Serum Institute of India into national programmes, subject to global approvals and further evidence.

Socio-Economic Factors Contributing to High Burden:

• Lack of Awareness: Low awareness about cervical cancer, its causes, prevention, and treatment, especially in rural areas.
• Limited Screening: Inadequate access to and uptake of regular cervical cancer screening (Pap tests, HPV DNA tests) in many parts of India.
• Reproductive Health Taboos: Stigma and discomfort surrounding discussions about sexual and reproductive health prevent women from seeking timely medical advice.
• Healthcare Access: Disparities in healthcare access, particularly for women in remote or socio-economically disadvantaged regions.
• Late Presentation: Many cases are diagnosed at advanced stages, leading to poor prognosis

Way forward for successful implementation of India’s HPV vaccination drive

India’s nationwide HPV vaccination initiative is a transformative step toward cervical cancer elimination. However, sustained success requires a multi-dimensional strategy.

1. Integrate HPV vaccination into the Universal Immunization Programme (UIP)

Institutionalising HPV vaccination within the UIP will ensure:

• Stable financing and procurement
• Routine delivery through existing immunisation infrastructure
• Long-term sustainability beyond campaign mode

2. Expand coverage to the full WHO-recommended age group

While the current focus is on 14-year-old girls, India should progressively cover 9–14 years (and eventually both genders), in line with World Health Organization recommendations for maximum herd protection.

3. Promote indigenous vaccine adoption and self-reliance

Scaling up domestic production of vaccines such as CERVAVAC by Serum Institute of India can:

• Reduce costs
• Ensure supply security
• Strengthen India’s vaccine diplomacy and health sovereignty

4. Strengthen awareness and community engagement

Targeted Information, Education, and Communication (IEC) campaigns involving:

• Schools and teachers
• ASHA and Anganwadi workers
• Women’s self-help groups

can address myths linking HPV vaccination to sexual behaviour and improve acceptance.

5. Integrate vaccination with cervical cancer screening programmes

A life-course approach should combine:

• Adolescent HPV vaccination
• Adult screening (Pap smear / HPV testing)
• Early treatment services

This aligns with WHO’s 90-70-90 cervical cancer elimination strategy.

6. Strengthen digital tracking and follow-up systems

Using platforms like U-WIN for:

• Beneficiary identification
• Coverage monitoring
• Adverse event tracking

will improve programme efficiency and accountability.

7. Ensure equity and last-mile delivery

Special strategies are needed for:

• Rural and tribal populations
• School drop-out girls
• Urban slums

Mobile vaccination teams and school-based campaigns can improve reach

8. Move toward gender-neutral HPV vaccination in the long term

Currently the programme prioritises girls due to the direct burden of cervical cancer. However, vaccinating boys can:

• Reduce HPV transmission and create herd immunity
• Prevent HPV-related cancers in males
• Accelerate cervical cancer elimination

Example: Australia extended HPV vaccination it to boys in 2013. India may progressively expand coverage to boys as resources and vaccine supply increase.

9. Adopt decentralised implementation using successful state models

India can draw lessons from Sikkim, the first state to implement universal HPV vaccination with high coverage.

Key lessons include:

• Strong political commitment
• School-based delivery systems
• Community awareness campaigns
• Robust monitoring

Scaling nationally requires state-specific strategies, recognising variations in health infrastructure and socio-cultural contexts across states.

Conclusion:

If India integrates HPV vaccination into routine immunisation, expands coverage, promotes indigenous vaccines, and combines it with screening and awareness, the country can substantially reduce cervical cancer burden and move toward elimination in line with global health targets.